The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL.

摘要: Abstract The conditional survival of patients after frontline therapy for diffuse large B-cell lymphoma (DLBCL) approaches that the general population once have survived disease free 2 years. We sought to determine among with relapsed de novo DLBCL successfully undergoing an autologous stem-cell transplant (ASCT) first relapse. A total 478 DLBCL, 1 treatment from Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) and LY.12, were included. Patients followed prospectively ASCT a median 5.3 8.2 years, respectively. Individual patient data analyzed event-free (EFS) overall survival. Standardized mortality ratios (SMRs) estimated using French Canadian life tables. EFS estimates declined each year follow-up 50.1% (95% confidence interval [CI]: 43.7% 56.3%) 43.4% CI: 36.7% 49.9%) at 5 years CORAL rate death stabilized achieved least 4 EFS. Compared age- sex-matched population, SMR was significantly higher until ASCT, when values no longer statistically significant. continue they event These observations can help endpoints future clinical trials this counseling. This trial registered www.clinicaltrials.gov as #NCT00078949.